TY - JOUR
T1 - A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia
AU - Klein, Klara
AU - Kollmann, Sebastian
AU - Hiesinger, Angela
AU - List, Julia
AU - Kendler, Jonatan
AU - Klampfl, Thorsten
AU - Randhawa, Mehak
AU - Trifinopoulos, Jana
AU - Maurer, Barbara
AU - Grausenburger, Reinhard
AU - Bertram, Christof A
AU - Moriggl, Richard H
AU - Rülicke, Thomas
AU - Mullighan, Charles G
AU - Witalisz-Siepracka, Agnieszka
AU - Walter, Wencke
AU - Hoermann, Gregor
AU - Sexl, Veronika
AU - Gotthardt, Dagmar
N1 - Publisher Copyright:
© 2024 American Society of Hematology
PY - 2024/6/13
Y1 - 2024/6/13
N2 - Patients with T- and natural killer (NK)-cell neoplasms frequently have somatic STAT5B gain-of-function mutations. The most frequent STAT5B mutation is STAT5B
N642H, which is known to drive murine T-cell leukemia, although its role in NK-cell malignancies is unclear. Introduction of the STAT5B
N642H mutation into human NK-cell lines enhances their potential to induce leukemia in mice. We have generated a mouse model that enables tissue-specific expression of STAT5B
N642H and have selectively expressed the mutated STAT5B in hematopoietic cells (N642H
vav/+) or exclusively in NK cells (N642H
NK/NK). All N642H
vav/+ mice rapidly develop an aggressive T/NKT-cell leukemia, whereas N642H
NK/NK mice display an indolent NK-large granular lymphocytic leukemia (NK-LGLL) that progresses to an aggressive leukemia with age. Samples from patients with NK-cell leukemia have a distinctive transcriptional signature driven by mutant STAT5B, which overlaps with that of murine leukemic N642H
NK/NK NK cells. To our knowledge, we have generated the first reliable STAT5B
N642H-driven preclinical mouse model that displays an indolent NK-LGLL progressing to aggressive NK-cell leukemia. This novel in vivo tool will enable us to explore the transition from an indolent to an aggressive disease and will thus permit the study of prevention and treatment options for NK-cell malignancies.
AB - Patients with T- and natural killer (NK)-cell neoplasms frequently have somatic STAT5B gain-of-function mutations. The most frequent STAT5B mutation is STAT5B
N642H, which is known to drive murine T-cell leukemia, although its role in NK-cell malignancies is unclear. Introduction of the STAT5B
N642H mutation into human NK-cell lines enhances their potential to induce leukemia in mice. We have generated a mouse model that enables tissue-specific expression of STAT5B
N642H and have selectively expressed the mutated STAT5B in hematopoietic cells (N642H
vav/+) or exclusively in NK cells (N642H
NK/NK). All N642H
vav/+ mice rapidly develop an aggressive T/NKT-cell leukemia, whereas N642H
NK/NK mice display an indolent NK-large granular lymphocytic leukemia (NK-LGLL) that progresses to an aggressive leukemia with age. Samples from patients with NK-cell leukemia have a distinctive transcriptional signature driven by mutant STAT5B, which overlaps with that of murine leukemic N642H
NK/NK NK cells. To our knowledge, we have generated the first reliable STAT5B
N642H-driven preclinical mouse model that displays an indolent NK-LGLL progressing to aggressive NK-cell leukemia. This novel in vivo tool will enable us to explore the transition from an indolent to an aggressive disease and will thus permit the study of prevention and treatment options for NK-cell malignancies.
KW - Animals
KW - Cell Lineage/genetics
KW - Disease Models, Animal
KW - Humans
KW - Killer Cells, Natural/metabolism
KW - Leukemia, Large Granular Lymphocytic/genetics
KW - Mice
KW - Mice, Transgenic
KW - Mutation
KW - STAT5 Transcription Factor/genetics
UR - http://www.scopus.com/inward/record.url?scp=85190982974&partnerID=8YFLogxK
U2 - 10.1182/blood.2023022655
DO - 10.1182/blood.2023022655
M3 - Journal article
C2 - 38498036
SN - 0006-4971
VL - 143
SP - 2474
EP - 2489
JO - Blood
JF - Blood
IS - 24
ER -